
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Troculeucel
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : NKGen Biotech
Deal Size : Undisclosed
Deal Type : Partnership
NKGen and HekaBio Enter Partnership to Bring Novel NK Cell Therapy to Japan
Details : NKGen Biotech and HekaBio will bring SNK01 (troculeucel), an autologous NK cell therapy, for treating Alzheimer’s and Parkinson’s diseases to Japan via accelerated regenerative medicine pathways.
Product Name : SNK01
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 17, 2025
Lead Product(s) : Troculeucel
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : NKGen Biotech
Deal Size : Undisclosed
Deal Type : Partnership

Contact Us!